Company intelligence / Profile preview
VAR2 Pharmaceuticals
- Ownership
- Private
- Development stage
- Phase 1
Overview
Preclinical studies show that Vartumabs selectively target tumors with high specificity and minimal off-target effects. ADC formulations have demonstrated curative effects in various mouse models without significant toxicity. The first-in-human Phase 0 imaging study is underway to assess biodistribution and pharmacokinetics in patients with solid tumors. Initial patient enrollment was completed December 2024. Results from this study will inform future efficacy trials.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADCs)Bispecific antibodies (CD3-bispecifics)Single-chain variable fragments (scFvs)
- Industry
- Biotech
Drug pipeline
14 assets13 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on VAR2 Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VAR2 Pharmaceuticals.